Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 96

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 96
---
. We depend on CIBIC, one of our indirect shareholders, for a substantial part of our revenues, and if the Commercialization Agreement is terminated, our business and results of operations would be materially adversely affected. On January 3, 2017, Heritas Argentina entered into a commercialization agreement with CIBIC, as amended on October1, 2018 by Addendum No.1, a shareholder of the Parent, in which we appointed CIBIC as exclusive agent for the commercialization of Heritas Diagnostics tests in Argentina (the “Commercialization Agreement”). The Commercialization Agreement is valid for 30 years from the signing date and will be automatically renewed for ten -yearperiods unless terminated with proper notice. 24 The Commercialization Agreement may be terminated (i) when its 30 -yearterm is completed, (ii) if one of the parties becomes insolvent, petitions for bankruptcy or begins liquidation, or (iii) by Heritas Argentina in the event of a change of control of CIBIC. In the event that the Commercialization Agreement is terminated, it may be difficult for Heritas Argentina to find a new agent for the commercialization of Heritas Diagnostics tests in Argentina and to agree on pricing on commercially acceptable terms. In this scenario, Heritas Argentina may be unable to timely develop its sales capabilities and to organize a marketing strategy, which could adversely affect its business and results of operations. The termination of the Commercialization Agreement could negatively impact our revenues. We are exposed to risks relating to our relationship with related parties. We currently have related party transactions with Bioceres S.A., CIBIC and Theo, which are indirect shareholders in our Company. In all related party transactions, there is a risk that even if our personnel negotiating on our behalf with the related party are striving to ensure that the terms of the transactions are arms -length, the related party’s influence may be such that the transaction terms could be viewed as favorable to that related party (leading to, among other things, potential negative consequences related to transfer pricing). In addition, the related party transaction could be perceived as a potential conflict of interest since the transaction may benefit the related party. Such conflicts could cause an individual in our management to seek to advance his or her economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest created by related party transactions could impair the confidence of our investors. Doing business internationally, especially in emerging markets, creates operational risk for our business. Conducting